NASDAQ$HOWL
Werewolf Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Werewolf Therapeutics reported Q1 2025, net loss of $18.1M, diluted EPS of $-0.40.
For Q1 2025, Werewolf Therapeutics reported a net loss of $18.1M, diluted EPS was $-0.40. Management discusses operating trends, capital, and sector risks in the quarterly filing.
- Net loss $18.1M.
- Diluted EPS $-0.40.
- Werewolf Therapeutics highlights liquidity, execution, and sector-specific risks in MD&A.
Headline financials
Revenue & EPS history
Werewolf Therapeutics · Revenue · Quarterly
$0
Forward guidance
Clinical-stage biotech filers emphasize trial milestones, regulatory paths, and cash runway; product revenue is limited or absent.
Tailwinds
- Pipeline progress and partnership optionality.
- Cash balances funding operations into upcoming catalysts.
- Regulatory designations where applicable.
Headwinds
- Trial failure or regulatory delay risk.
- Dilution from equity raises.
- No near-term product revenue for most programs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+0.1%
Avg return
Earnings day
-0.8%
Avg return
5 days after
+2.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+16.5%
Q2 2022
Best reaction
-7.4%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.5% | -2.3% | -39.8% | |
| Q3 2025 | -5.0% | -7.4% | -22.0% | |
| Q2 2025 | -1.5% | -5.9% | +5.9% | |
| Q1 2025 | +0.9% | -2.7% | +9.9% | |
| Q4 2024 | -0.9% | -3.4% | -21.5% | |
| Q3 2024 | -5.7% | -11.9% | -26.2% | |
| Q1 2024 | -1.6% | -9.9% | -15.0% | |
| Q4 2023 | -7.4% | -6.1% | -15.8% | |
| Q3 2023 | -0.9% | +3.6% | +28.8% | |
| Q2 2023 | +3.2% | -0.8% | -0.4% | |
| Q1 2023 | -3.3% | -9.9% | +11.2% | |
| Q4 2022 | +6.1% | +9.2% | +3.1% | |
| Q3 2022 | +2.3% | -5.0% | -19.4% | |
| Q2 2022 | +16.5% | +21.3% | +55.2% | |
| Q1 2022 | +3.3% | -12.1% | +1.7% | |
| Q4 2021 | +0.5% | +9.5% | +12.6% | |
| Q3 2021 | +1.8% | +1.6% | -6.7% | |
| Q3 2020 | +1.8% | +1.6% | -6.7% | |
| Q2 2021 | -3.5% | -2.7% | +13.9% | |
| Q2 2020 | -3.5% | -2.7% | +13.9% | |
| Q1 2021 | +1.0% | +5.8% | +22.4% | |
| Q1 2020 | +1.0% | +5.8% | +22.4% | |
| Q4 2020 | +1.0% | +5.8% | +22.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro